RestructuringAug 7, 2026, 04:05 PM
aTyr Pharma Restructures, Cuts 60% Workforce; Q2 Cash $58.9M
AI Summary
aTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to prioritize its efzofitimod program in interstitial lung disease (ILD). This move is expected to reduce annualized operating expenses by $13 million and extend the company's cash runway into late 2028. The company reported $58.9 million in cash and investments at the end of Q2 2026, with a net loss of $10.3 million. Key clinical updates include awaiting FDA comments on its Phase 3 efzofitimod protocol by August 2026 and expecting topline results from the Phase 2 EFZO-CONNECT™ study in Q1 2027.
Key Highlights
- Workforce reduced by approximately 60% as part of corporate restructuring.
- Restructuring expected to reduce annualized operating expenses by $13 million starting Q4 2026.
- Ended Q2 2026 with $58.9 million in cash, cash equivalents, restricted cash, and investments.
- Cash runway extended into late 2028 based on current operations.
- FDA comments on efzofitimod Phase 3 protocol for pulmonary sarcoidosis expected by end of August 2026.
- Enrollment completed for Phase 2 EFZO-CONNECT™ study; topline results expected Q1 2027.
- Q2 2026 R&D expenses were $6.7 million, down from $15.4 million in Q2 2025.
- Q2 2026 net loss was $10.3 million, compared to $19.5 million in Q2 2025.
Price Impact
More from ATYR